Mantle Cell Lymphoma: FDA Grants Breakthrough Therapy Designation to Acalabrutinib

Share this content:
The FDA granted Breakthrough Therapy Designation to acalabrutinib for patients with MCL who have received at least 1 line of therapy.
The FDA granted Breakthrough Therapy Designation to acalabrutinib for patients with MCL who have received at least 1 line of therapy.

The US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to acalabrutinib for patients with mantle cell lymphoma (MCL) who have previously received at least 1 line of therapy.1

Acalabrutinib previously received Orphan Drug Designation from the FDA to treat patients with MCL, and from the European Commission to treat patients with chronic lymphocytic leukemia (CLL), MCL, and Waldenström macroglobulinemia.

The FDA granted breakthrough designation based on data from the phase 2 ACE-LY-004 trial (ClinicalTrials.gov Identifier: NCT02213926), for which researchers enrolled 124 patients with previously treated MCL.

A previous clinical trial (ClinicalTrials.gov Identifier: NCT02029443) that investigated the effects of acalabrutinib in 61 patients with CLL demonstrated safety and efficacy. At a median follow-up of 14.3 months, patients exhibited an overall response rate of 95%.2

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is being investigated in more than 25 clinical trials to treat multiple B cell and other cancers.

RELATED: Mantle Cell Lymphoma: Evaluating the Treatment Landscape

The FDA grants breakthrough therapy designation to medications that treat serious conditions and early analyses demonstrate clinical benefit. Treatments must also provide evidence for improvement on clinically significant endpoints over standard therapies, and must address unmet medical needs.

References

  1. Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma [news release]. Gaithersburg, MD: AstraZeneca; August 1, 2017.  https://www.astrazeneca.com/media-centre/press-releases/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-01082017.html. Accessed August 1, 2017.
  2. Byrd J, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374:323-32.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters